The ability of transplanted CD7+ progenitors generated in the present culture system to treat T-cell deficiencies will be investigated in a forthcoming clinical trial (NCT03879876) that has been approved by the French Drug Agency. The gene discussed is CD7; the disease is congenital T-cell immunodeficiency.